Post — 10 Min Read

Labskin Secures Access to the Sars-Cov-2 Virus

Labskin secures access to the Sars-Cov-2 virus to assess its impact on human skin without exposing human volunteers to dangerous clinical trial contamination risk.

  • Study the transferability of viral particles from materials to skin
  • Assess the ability of the virus to remain infective while on the skin surface
  • Quantify the efficacy of mouthwash and dental care products
  • Quantify the efficacy of soap washing and hand sanitisers

As the Covid-19 pandemic continues to rage across the world, the phrase ‘we’re all in this together’ resonates. With this in mind Labskin continues to do its part in the global fight and is deploying it’s resources to assist in discovering Covid-19 solutions.

As part of our efforts we have secured access to the SARS – CoV – 2 virus in a Category 3 lab with partners in the University of Aberdeen.

Below we outline some of the projects we are involved with. If you or your company can help or have any ideas to progress these, please get in touch. If you have a project where we may be able to help, we are eager to hear from you. We’re all in this together.

Skin, Transmissibility and Infection Control

We are coating our human skin model with SARS-CoV-2 to test how long it remains viable on human skin. This allows us to investigate the efficacy of washes, sanitizers and anti-viral treatments.

The Labskin team is testing the Covid virus on skin, to determine:

  • If the virus is transmissible from surfaces to airways via skin by measuring its viability when recovered from surface(s) to skin.
  • To show that sanitizers kill the virus on skin (this is anecdotally assumed to be correct based on WHO research on other bacteria, but not, as far as we know, proved for Covid-19).
  • To show the reduction of titer and/or virulence.

Dental Practice COVID19 Infection Risk

With the ability of Labskin to produce sensitive skin types we are also investigating consumer and pre-procedural mouthwash dental care products that may mitigate the risk of transmission in dental practices using Labskin specifically grown to mimic the oral and nasal cavities.

Given the widespread transmission of SARS-CoV-2, and reports of its spread to health care providers, dental professionals are at high risk of infection and can become potential transmission vectors for the disease. These risks can be attributed to the unique nature of dental interventions, which include aerosol generation, handling of sharps, and proximity of the provider to the patient’s oropharyngeal region. In addition, if adequate precautions are not taken, the dental care environment can potentially expose patients to cross contamination.

Gerard Brandon – CEO of Integumen plc

Gerard Brandon comments:

“Labskin is grateful for the opportunity and support of the University of Aberdeen to facilitate testing of the Covid – 19 virus on our cloned human skin, simulating soft nasal tissue and oral cavity environments to study the effects of a variety of products and ingredients in a secure CL3 laboratory environment without exposing human volunteers to dangerous and challenging clinical trial contamination risk.

Our Labskin full-thickness human skin model was specifically developed for the study of the human skin microflora and the microbiota/host interactions. Its dryness and barrier function create an ideal environment where individual or multiple microbial species can thrive to form a stable community. Labskin can be colonized with microorganisms belonging to the three domains of life and these can be infected with bacterial, fungal and viral pathogens.

The more knowledge we have about SARS-CoV-2 – how we spread it and more importantly, how to contain that spread – the better equipped we all are to fight this virus.”